akhatri

/akhatri

About akhatri

This author has not yet filled in any details.
So far akhatri has created 90 blog entries.

3 products re-classified as special containers from February 2026

Following representations from Community Pharmacy England, the Department of Health and Social Care (DHSC) has re-determined that the following products will be granted special container status from 1 February 2026. Generic drug name (dm+d descriptor) Brand and/or manufacturer Pack Size Special container Relugolix 120mg tablets Orgovyx® 120mg tablets (Accord-UK Ltd) 30 tablet Complete pack Salbutamol 2.5mg/2.5ml [...]

The post 3 products re-classified as special containers from February 2026 appeared first on Community Pharmacy England.

By |January 30th, 2026|Lexpos News|Comments Off on 3 products re-classified as special containers from February 2026

National Patient Safety Alert: Class 1 Medicines Recall Notification: Recall of Quetiapine Oral Suspension (unlicensed medicine), manufactured by Eaststone Limited

Eaststone Limited is initiating a recall of all batches of quetiapine oral suspension products due to a potential risk of overdose, which could have consequences for the safety of patients. This alert is for action by: ​primary and secondary care, specifically those involved in pharmacy services, including dispensing general practices and those involved in the prescribing for mental health conditions. This is [...]

The post National Patient Safety Alert: Class 1 Medicines Recall Notification: Recall of Quetiapine Oral Suspension (unlicensed medicine), manufactured by Eaststone Limited appeared first on Community Pharmacy England.

By |January 29th, 2026|Lexpos News|Comments Off on National Patient Safety Alert: Class 1 Medicines Recall Notification: Recall of Quetiapine Oral Suspension (unlicensed medicine), manufactured by Eaststone Limited

MHRA Drug Safety Update: GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Drug Safety Alert regarding Glucagon-Like Peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. The product information for all GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists (dulaglutide, exenatide, liraglutide, semaglutide and tirzepatide) has been further updated to highlight the potential [...]

The post MHRA Drug Safety Update: GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings appeared first on Community Pharmacy England.

By |January 29th, 2026|Lexpos News|Comments Off on MHRA Drug Safety Update: GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings

NHSBSA ‘Hints & Tips’ – Issue 62

The NHS Business Services Authority (NHSBSA) produces a quarterly newsletter called “Hints & Tips for dispensing contractors”. The latest edition (Issue 62) contains some useful information and advice on: New address for end of month batch submissions Pharmacy Quality Scheme: Declaration window opens in Manage Your Service on 2 February 2026 Pharmacy Quality Scheme: Antimicrobial [...]

The post NHSBSA ‘Hints & Tips’ – Issue 62 appeared first on Community Pharmacy England.

By |January 29th, 2026|Lexpos News|Comments Off on NHSBSA ‘Hints & Tips’ – Issue 62

MHRA Drug Safety Update: Isotretinoin – changes to prescribing guidance and additional risk minimisation measures

The Commission on Human Medicines (CHM) has endorsed changes to the risk minimisation measures for isotretinoin, following a review of the impact of the measures implemented in 2023. We ask healthcare professionals to review these new measures and supporting materials and integrate them into their clinical practice. Second prescriber no longer required plus updated risk [...]

The post MHRA Drug Safety Update: Isotretinoin – changes to prescribing guidance and additional risk minimisation measures appeared first on Community Pharmacy England.

By |January 22nd, 2026|Lexpos News|Comments Off on MHRA Drug Safety Update: Isotretinoin – changes to prescribing guidance and additional risk minimisation measures